BARDA – Advanced Research and Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures

November 15, 2017 by School of Medicine Webmaster

SOM faculty interested in applying for this program should contact Steve Wasserman (ssw3an), who can put them in touch with The Conafay Group, a consulting firm that is assisting the school with obtaining DoD and defense-related funding.

The Biodefense Advanced Research and Development Authority (BARDA) released its FY18 Broad Agency Announcement (BAA), soliciting proposals for advanced research and development of medical countermeasures (MCM).  BARDA seeks proposals to detect, contain, and treat chemical, biological, radiological, and nuclear (CBRN) agents; pandemic influenza; and emerging infectious diseases.  The BAA highlights 14 areas of interest listed below, which include various technologies, vaccines, therapeutics, diagnostics, and devices to address these threats and to protect U.S. civilian health.

Areas of interest

  • Chemical, biological, radiological, and nuclear (CBRN) Vaccines
  • Antitoxins and Therapeutic Proteins
  • Antibacterials
  • Radiological/Nuclear Threat Medical Countermeasures
  • Chemical Threat Medical Countermeasures
  • Burn Medical Countermeasures
  • Diagnostics
  • Influenza and Emerging Infectious Diseases (IEID) Vaccines
  • Influenza and Emerging Infectious Diseases (IEID) Therapeutics
  • Respiratory Protective Devices
  • Ventilators
  • MCM Production Platform Systems
  • Modeling as an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats
  • Visual Analytics an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats

BARDA’s mission “is to develop and procure medical countermeasures that address the public health and medical consequences of CBRN accidents, incidents and attacks; pandemic influenza; and emerging infectious diseases.” BARDA’s priorities and programs closely align with the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Strategic Plan, as well as the Department of Health and Human Services (HHS) Pandemic Influenza Plan and other interagency efforts to promote and protect the nation’s public health.  Per the BAA, interested applicants should be aware of these efforts and agencies’ roles in the national MCM enterprise.

BARDA released the BAA in advance of its 2017 Industry Day, which invites interested industry, academia, and government agencies to engage with BARDA staff to share best practices for collaboration and to discuss recent successes and future visions.  Repeatedly, BARDA emphasized the value of its TechWatch program, which is a web-based meeting platform to discuss concepts, technologies, and capabilities.  The benefit of TechWatch is BARDA’s ability to invite diverse program staff and expertise to participate, as well as other agency officials, including those from the Department of Defense (DOD), the National Institutes of Health (NIH), and the Food and Drug Administration, among others.  BARDA strongly encourages those interested in the BAA to submit a meeting request through TechWatch, prior to submitting a BAA white paper.  Program managers can provide candid feedback and ideas for additional collaborators.  Once a white paper is submitted through the BAA process, all communication must go through the contracting office.

Stage One of the application process requires a cover sheet, a quad chart, and a white paper.  The BAA includes specific instructions for these requirements.  BARDA has instituted quarterly deadlines for Stage One submissions through 2019.  Applicants will receive a notice on whether to submit a full proposal within 90 days of the submission deadline. An invitation is required to submit a full proposal.

Application Deadline: 

  • Stage One (quad charts and white papers) – January 31, April 30, July 31, and October 31, in both 2018 and 2019
  • Invited, full proposals are due any day during the open period for the BAA (i.e., through October 31, 2019).

Total Funding and Award Size:  BARDA anticipates issuing multiple awards of various sizes.  Total available funding is subject to change depending on budget and emerging priorities.

Eligibility:  The BAA is open to all “single entities or teams from private sector organizations, government laboratories, and academic institutions.”  Those interested are encouraged to verify the BAA for full eligibility requirements and award restrictions.


Information about BARDA and BARDA Industry Day:

BARDA’s TechWatch program:

PHEMCE Strategic Plan:

HHS Pandemic Influenza Plan:

Filed Under: Funding Opportunities